Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1614235 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GSK1614235 | EXPERIMENTAL | Glucose lowering agent under investigation. |
| Sitagliptin | ACTIVE_COMPARATOR | Glucose lowering comparator |
| Placebo | PLACEBO_COMPARATOR | Placebo to match GSK1614235 and placebo to match Sitagliptin |
| Name | Type | Description |
|---|---|---|
| GSK1614235 | DRUG | Glucose lowering in Type 2 Diabetes Mellitus |
| Sitagliptin | DRUG | Glucose lowering in Type 2 Diabetes Mellitus |
| Placebo | OTHER | Comparator |
Inclusion Criteria Part A: * Subjects with documented type 2 diabetes mellitus diagnosis whose HbA1c levels are \>7 and at or less than 9.5%; at screening, who are either controlled by diet alone, or are on monotherapy with oral sulfonylureas, DPP-IV inhibitors (e.g. sitagliptin), or metformin. * M...
GSK1614235 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is designed as a glucose lowering drug and is currently in Phase 1 clinical development. The drug is not yet approved and remains under investigation for this metabolic condition.
GSK1614235 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Type 2 Diabetes Mellitus.
GSK1614235 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under evaluation for the treatment of Type 2 Diabetes Mellitus.
GSK1614235 has one completed Phase 1 clinical trial, identified as NCT00976261. This was a two-part study conducted in subjects with Type 2 Diabetes and healthy volunteers, involving 72 participants across the United States, France, Germany, and the United Kingdom. The trial was randomized, double-blind, and placebo-controlled.
GSK1614235 is a new glucose lowering drug being developed to treat Type 2 Diabetes Mellitus. It is a small molecule designed to lower blood glucose levels. The drug is currently in Phase 1 clinical trials and is not yet approved for clinical use.